NCT01937975View on ClinicalTrials.gov

The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 6, 2013

Primary Completion Date

December 17, 2013

Study Completion Date

December 17, 2013

Conditions
Chronic Hepatitis CRenal Impairment
Interventions
DRUG

Grazoprevir

100 mg oral tablet administered once a day for 10 days

DRUG

Elbasvir

50 mg oral tablet administered once a day for 10 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) | Biotech Hunter | Biotech Hunter